Baxter International
Search results
A global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. Read more.
Baxalta ( Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound' [2]) is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. [1]
Baxalta Pharmaceutical Company is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
Dublin, Ireland – June 3, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today completed its previously announced combination with Baxalta Incorporated (NYSE: BXLT), creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions.
Jun 28, 2024 · Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
Jan 19, 2016 · Baxalta (BXLT) describes their business this way: “Baxalta is a global, innovative biopharmaceutical leader with a sustainable portfolio of differentiated therapies that seek to address unmet...
Mar 19, 2016 · On July 1, 2015, Baxter International (BAX) separated its Biosciences division into a new entity named Baxalta (BXLT). The company did this in an effort to divest its risky business segments...
Jan 21, 2016 · Baxalta, Inc. (NYSE: BXLT) is a biotechnology spin-off from its parent company Baxter (NYSE: BAX) with its focus on rare hematological disorders and orphan cancers. The company has diversified...
Jan 11, 2016 · Shire ’s agreement to buy Baxalta for $32bn marks the biggest deal in the 30-year history of the UK-listed company and promises to propel the combined group to the cusp of the world’s 20 largest...
Nov 23, 2017 · Baxter International Inc. (NYSE: BAX) (“Baxter”) announced today the preliminary results of Baxter’s previously announced offer to exchange up to 13,360,527 shares of common stock of Baxalta Incorporated (NYSE: BXLT) (“Baxalta”) that are currently owned by Baxter for shares of Baxter common stock. The exchange offer expired at 11:59 p.m.,
